Replies to post #65442 on Anavex Life Sciences Corp (AVXL)

[Amatuer17]

ALZ does not have an effective treatment - so there is need for some good drugs.

The market is not crowded with competition - so 2 drugs should not be an issue.

For us AVXL investors - the important thing is - whether A2-73 works or not - and if it will lead to buyout so we make good profit.

[HANUMAN]

Methylene Blue has been around for years in the operating room and for diagnostic use. We have injected it in patient's total hip joints and other areas to evaluate hip and knee joints for communication with drainage sites. If the drainage comes out blue, you know there is communication, and likely infection. I doubt very much that it is under patent protection, as it is relatively cheap.

[orveko_inc]

Methylene Blue has apparently been around for a long time. Perhaps Orveko may be able to comment about whether Methylene Blue or its molecule by itself is perhaps not subject to patent, and the significance of the patent that Anavex has on the combination of Methylene Blue and AVXL 2-73 for cancer and neuropathic pain , the patent that Anavex has on AVXL 2-73, and whether Anavex needs a patent on the combination of Methylene Blue and AVXL 2-73 for the treatment of AD?

One of the claims in U.S. patent 9180106 covers a combination of A2-73 + methylene blue for the treatment of melanoma (the patent application covered "cancer and neuropathic pain," but the final patent is only for melanoma). On the surface, this is not very significant and does not cover this combination for the treatment of Alzheimer's or other neurodegenerative diseases (another patent would be required). However, deeper down this could be important. First (and most important), the two compounds appear to be safe when used together. Second, there is pre-clinical evidence for a synergistic relationship between A2-73 and methylene blue for at least one indication (hence the patent). Third, A2-73 and methylene blue (via TauRx's LMTX) are being tested independently as treatments for Alzheimer's. Should both prove beneficial, the fact that they are safe together and potentially synergistic could make the two drugs pals and not competitors.

Alzheimer's is complicated and likely requires a mulit-faceted approach. I doubt we will ever see "one pill to cure them all." Combinations of safe and effective therapies will almost certainly be the way to treat this and other neurodegenerative diseases in the not-so-distant future. So, other potential therapies (like LMTX) are less competition and more vehicles for greater exposure for A2-73 if you ask me.